| pubmed-article:8624375 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:8624375 | lifeskim:mentions | umls-concept:C2926735 | lld:lifeskim |
| pubmed-article:8624375 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8624375 | pubmed:dateCreated | 1996-6-25 | lld:pubmed |
| pubmed-article:8624375 | pubmed:abstractText | A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p = 0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of > 12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievement of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the suppression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. | lld:pubmed |
| pubmed-article:8624375 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8624375 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8624375 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8624375 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8624375 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8624375 | pubmed:issn | 0939-5555 | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:LechnerKK | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:SchneiderBB | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:ThalhammerFF | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:JägerUU | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:PabingerII | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:GeisslerKK | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:HaasO AOA | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:KnöblPP | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:GisslingerHH | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:KyrleP APA | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:LaczikaKK | lld:pubmed |
| pubmed-article:8624375 | pubmed:author | pubmed-author:MitterbauerMM | lld:pubmed |
| pubmed-article:8624375 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8624375 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:8624375 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8624375 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8624375 | pubmed:pagination | 216-22 | lld:pubmed |
| pubmed-article:8624375 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:meshHeading | pubmed-meshheading:8624375-... | lld:pubmed |
| pubmed-article:8624375 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8624375 | pubmed:articleTitle | Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. | lld:pubmed |
| pubmed-article:8624375 | pubmed:affiliation | Department of Medicine I, University of Vienna, Austria. | lld:pubmed |
| pubmed-article:8624375 | pubmed:publicationType | Journal Article | lld:pubmed |
